Clinical Trial Update: Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

View source ↗

Summary

Global observational registry MOS investigates the safety of Elfabrio (migalastat) in pregnant women with Fabry disease and their infants during pregnancy and b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Elfabrio (migalastat)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Fabry Disease, Pregnancy | Status: RECRUITING